(Q34763184)

English

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina (English)

1 reference

Europe PubMed Central

4 August 2017

0 references

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

0 references

author name string

A Carrá

1

1 reference

Europe PubMed Central

4 August 2017

P Onaha

2

1 reference

Europe PubMed Central

4 August 2017

G Luetic

3

1 reference

Europe PubMed Central

4 August 2017

M Burgos

4

1 reference

Europe PubMed Central

4 August 2017

E Crespo

5

1 reference

Europe PubMed Central

4 August 2017

N Deri

6

1 reference

Europe PubMed Central

4 August 2017

M Halfon

7

1 reference

Europe PubMed Central

4 August 2017

G Jaacks

8

1 reference

Europe PubMed Central

4 August 2017

A López

9

1 reference

Europe PubMed Central

4 August 2017

V Sinay

10

1 reference

Europe PubMed Central

4 August 2017

C Vrech

11

1 reference

Europe PubMed Central

4 August 2017

publication date

1 April 2008

1 reference

Europe PubMed Central

4 August 2017

European Journal of Neurology

1 reference

Europe PubMed Central

4 August 2017

15

1 reference

Europe PubMed Central

4 August 2017

4

1 reference

Europe PubMed Central

4 August 2017

386-393

1 reference

Europe PubMed Central

4 August 2017

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Natalizumab for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2008.02071.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2008.02071.X

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34763184&oldid=1607295093"